Pricing Log in Create free account

argenex SE (ARGX) vs Royalty Pharma PLC (RPRX)

argenex SE and Royalty Pharma PLC are both Biotechnology companies. argenex SE is the larger, with a market value of $56.3B against $39.0B — 1.4× the size. argenex SE trades at the lower P/E: 29.8× against 44.8×. argenex SE grew revenue faster over the last twelve months: 60.8% against 11.4%. argenex SE has the higher net margin (31.7% vs 0.00%) and the lower return on invested capital (0.00% vs 5.24%). Across the 20 metrics below, argenex SE leads on 12 and Royalty Pharma PLC on 8.

Valuation

Metric ARGX RPRX Biotechnology median
P/E 29.82 44.80 10.26
P/S 9.52 11.53 9.18
P/B 6.71 3.08 2.05
Price to free cash flow 40.96 23.33 24.81
EV/EBITDA 30.39 24.70 0.65
EV/Sales 8.92 14.60 8.98
Earnings yield 3.35% 2.23% (34.89%)
Free cash flow yield 2.44% 4.29% (24.52%)

Profitability

Metric ARGX RPRX Biotechnology median
Gross margin 90.21% 100.00% 65.16%
Operating margin 29.34% 57.14% 0.00%
Net margin 31.68% 0.00% 0.00%
Free cash flow margin 0.00% 113.11% 0.00%
Return on equity 0.00% 0.00% (50.12%)
Return on assets 0.00% 0.00% (45.60%)
Return on invested capital 0.00% 5.24% 0.00%

Growth

Metric ARGX RPRX Biotechnology median
Revenue growth (TTM) 60.84% 11.36% 6.26%
EPS growth (last fiscal year) 53.13% (6.81%) 29.88%
Revenue growth, 5-year CAGR 130.77% 2.30% 9.75%
Net income growth, 5-year CAGR 0.00% (4.59%) 0.00%

Health

Metric ARGX RPRX Biotechnology median
Debt to equity 0.00 0.88 0.00
Current ratio 5.12 1.29 4.89
Net debt to EBITDA (3.23) 5.22 1.01

Dividend

Metric ARGX RPRX Biotechnology median
Dividend yield — 1.37% 0.41%
Payout ratio — 0.66 —

Size

Metric ARGX RPRX Biotechnology median
Market cap 56.27b 38.95b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack